Research News

Discovery Paves Road for New Treatments to Prevent Blindness in Babies

Babies born with Retinopathy of prematurity (ROP), one of the most common causes of vision loss in children, stand to benefit from an exciting discovery made possible, in part, by Fighting Blindness Canada. The…

Valproic Acid as a Treatment for Retinitis Pigmentosa

Clinical trials of valproic acid for the treatment of retinitis pigmentosa began in both the USA and Korea in late 2011. As well, a smaller shorter open-label trial was begun in Japan….

One Year Results of Choroideremia Gene Therapy Trial

In January, follow-up results from the first six months of the British choroideremia gene therapy trial were published. At the Association for Vision Research and Ophthalmology meeting today, the team led by Dr. Robert…

First Gene Therapy Results for Choroideremia Suggest Cautious Optimism

The first human trial of a gene therapy for choroideremia has announced preliminary results on six people: two of these patients have experienced significant improvements in vision. The findings were published in…

Eyelea Approved to Treat Wet AMD in Canada

An additional treatment option for people with wet age-related macular degeneration (AMD) will soon be available in Canada. Health Canada has just approved Eyelea, a drug made and marketed by Bayer Inc….

Valproic Acid: The Perils of Using Drugs Off-Label

Almost three years ago, scientists at the University of Massachusetts Medical School reported on a preliminary clinical trial of the epilepsy drug, valproic acid, as potential treatment for autosomal dominant retinitis pigmentosa…

Join the Fight!

Learn how your support is helping to bring a future without blindness into focus! Be the first to learn about the latest breakthroughs in vision research and events in your community by subscribing to our e-newsletter that lands in inboxes the beginning of each month.